[1] Hagen P T, Scholz D G, Edwards W D. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts[J]. Mayo Clin Proc, 1984,59(1):17-20. [2] Windecker S, Wahl A, Nedeltchev K, et al. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke[J]. J Am Coll Cardiol, 2004,44(4):750-758. [3] Wahl A, Jüni P, Mono M L, et al. Long-term propensity score-matched comparison of percutaneous closure of patent foramen ovale with medical treatment after paradoxical embolism[J]. Circulation, 2012,125(6):803-812. [4] Bannan A, Shen R, Silvestry F E, et al. Characteristics of adult patients with atrial septal defects presenting with paradoxical embolism[J]. Catheter Cardiovasc Interv, 2009,74(7):1066-1069. [5] Kent D M, Ruthazer R, Weimar C, et al.An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke[J]. Neurology, 2013,81(7):619-625. [6] Ning M, Lo E H, Ning P C, et al.The brain's heart-therapeutic opportunities for patent foramen ovale (PFO) and neurovascular disease[J]. Pharmacol Ther, 2013, 139(2):111-123. [7] Sacco R L, Foulkes M A, Mohr J P, et al. Determinants of early recurrence of cerebral infarction. The Stroke Data Bank[J]. Stroke,1989,20(8):983-989. [8] Davis D, Gregson J, Willeit P, et al. Patent foramen ovale, ischemic stroke and migraine: systematic review and stratified meta-analysis of association studies[J]. Neuroepidemiology, 2013,40(1):56-67. [9] 陈晓峰, 陈宝成,于川. 青年脑卒中116例数字减影血管造影分析及病因探讨[J]. 中国煤炭工业医学杂志,2013,16(3):398. [10] 顾美娟, 王大力. 缺血性脑卒中预后风险述评[J]. 中国煤炭工业医学杂志,2015,18(2):339-342. [11] 张颖冬. 脑血管病相关性运动障碍的认识现状[J]. 中国脑血管病杂志,2014,11(2):57-63. [12] Harvey J R, Teague S M, Anderson J L, et al. Clinically silent atrial septal defects with evidence for cerebral embolization[J]. Ann Intern Med, 1986, 105(5):695-697. [13] Khositseth A, Cabalka A K, Sweeney J P, et al. Transcatheter Amplatzer device closure of atrial septal defect and patent foramen ovale in patients with presumed paradoxical embolism[J]. Mayo Clin Proc, 2004, 79(1):35-41. [14] Lamy C, Giannesini C, Zuber M, et al. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Atrial Septal Aneurysm[J]. Stroke, 2002, 33(3):706-711. [15] Homma S, Di Tullio M R, Sacco R L, et al. Characteristics of a patent foramen ovale associated with cryptogenic stroke. A biplane transesophageal echocardiographic study[J]. Stroke, 1994, 25(3):582-586. [16] De Castro S, Cartoni D, Fiorelli M, et al. Morphological and functional characteristics of patent foramen ovale and their embolic implications[J]. Stroke, 2000, 31(10):2407-2413. [17] Stone D A, Godard J, Corretti M C, et al. Patent foramen ovale: association between the degree of shunt by contrast transesophageal echocardiography and the risk of future ischemic neurologic events[J]. Am Heart J, 1996, 131(1):158-161. [18] Pandit A, Aryal M R, Pandit A A, et al.Amplatzer PFO occluder device may prevent recurrent stroke in patients with patent foramen ovale and cryptogenic stroke: a meta-analysis of randomised trials[J]. Heart Lung Circ, 2014,23(4):303-308. [19] Carroll J D, Saver J L, Thaler D E, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke[J]. N Engl J Med, 2013,368(12):1092-1100. [20] 张玉顺, 朱鲜阳. 卵圆孔未闭处理策略中国专家建议[J]. 心脏杂志, 2015, 27(4):373-379. [21] Braun M, Gliech V, Boscheri A, et al. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and mid-term follow-up results of three different device occludersystems[J]. Eur Heart J, 2004, 25(5):424-430. [22] Matsumura K, Gevorgyan R, Mangels D, et al.Comparison of residual shunt rates in five devices used to treat patent foramen ovale[J]. Catheter Cardiovasc Interv, 2014,84(3):455-463. [23] Caputi L, Butera G, Anzola G P, et al. Residual shunt after patent foramen ovale closure: preliminary results from italian patent foramen ovalesurvey[J]. J Stroke Cerebrovasc Dis, 2013, 22(7): e219-226. [24] Van de Bruaene A, Stroobants D, Benit E. Percutaneous closure of inter-atrial communications (atrial septal defect and patent foramen ovale): single-centre experience and mid-term follow-up[J]. Acta Cardiol, 2015,70(2):133-140. [25] Marchese N, Pacilli M A, Inchingolo V, et al.Residual shunt after percutaneous closure of patent foramen ovale with AMPLATZER occluder devices-influence of anatomic features: a transcranial Doppler and intracardiac echocardiography study[J]. EuroIntervention, 2013, 9(3):382-388. [26] 李世军, 岳庆雄,王苏平,等. 卵圆孔未闭介入封堵治疗及近期随访研究[J].中国循环杂志, 2014, 29(6):448-452. [27] von Bardeleben R S, Richter C, Otto J, et al. Long term follow up after percutaneous closure of PFO in 357 patients with paradoxical embolism: Difference in occlusion systems and influence of atrial septum aneurysm[J]. Int J Cardiol, 2009,134(1):33-41. |